Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

ALKS

Alkermes plc

Apr 18 • 04:00PM ET

23.76

Dollar change -0.25
Percentage change -1.04	%

Healthcare • Drug Manufacturers - Specialty & Generic • Ireland • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: IJR VTI VB CALF IWM VXF VBK IWO FBT IBB

Scroll to Statements

Index	RUT	P/E	11.48	EPS (ttm)	2.07	Insider Own	1.47%	Shs Outstand	166.98M	Perf Week	-4.92%
Market Cap	4.02B	Forward P/E	9.34	EPS next Y	2.55	Insider Trans	-0.63%	Shs Float	166.70M	Perf Month	-14.22%
Income	355.76M	PEG	0.46	EPS next Q	0.60	Inst Own	105.08%	Short Float	8.60%	Perf Quarter	-14.41%
Sales	1.66B	P/S	2.42	EPS this Y	84.68%	Inst Trans	-1.28%	Short Ratio	7.26	Perf Half Y	-7.60%
Book/sh	7.20	P/B	3.30	EPS next Y	-4.30%	ROA	19.68%	Short Interest	14.34M	Perf Year	-12.62%
Cash/sh	4.57	P/C	5.20	EPS next 5Y	24.80%	ROE	35.93%	52W Range	20.46 - 32.88	Perf YTD	-14.35%
Dividend Est.	-	P/FCF	11.38	EPS past 5Y	-	ROI	22.72%	52W High	-27.74%	Beta	0.62
Dividend TTM	-	Quick Ratio	2.50	Sales past 5Y	10.61%	Gross Margin	82.17%	52W Low	16.13%	ATR (14)	0.82
Dividend Ex-Date	-	Current Ratio	2.86	EPS Y/Y TTM	320.93%	Oper. Margin	17.44%	RSI (14)	28.95	Volatility	2.98% 2.89%
Employees	2100	Debt/Eq	0.31	Sales Y/Y TTM	49.61%	Profit Margin	21.39%	Recom	2.15	Target Price	35.42
Option/Short	Yes / Yes	LT Debt/Eq	0.30	EPS Q/Q	485.63%	Payout	0.00%	Rel Volume	0.91	Prev Close	24.01
Sales Surprise	4.21%	EPS Surprise	-50.83%	Sales Q/Q	23.89%	Earnings	May 01 BMO	Avg Volume	1.98M	Price	23.76
SMA20	-9.08%	SMA50	-14.69%	SMA200	-11.31%	Trades		Volume	1,798,839	Change	-1.04%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-19-24	Initiated	Robert W. Baird	Outperform	$37
Feb-20-24	Downgrade	UBS	Neutral → Sell	$25
Nov-20-23	Resumed	JP Morgan	Neutral	$33
Oct-24-23	Upgrade	Evercore ISI	In-line → Outperform
Oct-17-23	Initiated	UBS	Neutral	$31
Nov-03-22	Upgrade	Piper Sandler	Neutral → Overweight	$26 → $30
Oct-14-22	Upgrade	BofA Securities	Underperform → Neutral	$27 → $25
Aug-16-22	Initiated	Piper Sandler	Neutral	$26
Apr-22-22	Resumed	Goldman	Buy	$35
Apr-20-22	Initiated	Goldman	Buy	$35
Jan-27-22	Upgrade	Cantor Fitzgerald	Hold → Overweight	$32
Dec-01-21	Initiated	Citigroup	Neutral	$22
Oct-07-21	Upgrade	Jefferies	Hold → Buy	$36
Sep-02-21	Downgrade	BofA Securities	Neutral → Underperform	$27
Oct-15-20	Upgrade	Mizuho	Neutral → Buy	$19 → $24
Jul-30-20	Downgrade	Goldman	Neutral → Sell	$19 → $15
Feb-14-20	Reiterated	H.C. Wainwright	Neutral	$26 → $25
Feb-14-20	Downgrade	JP Morgan	Overweight → Neutral	$21
Feb-14-20	Downgrade	BofA/Merrill	Buy → Neutral	$31 → $20
Feb-06-20	Initiated	Mizuho	Neutral

Show Previous Ratings

Apr-17-24 04:00PM	Alkermes to Report First Quarter Financial Results on May 1, 2024 (PR Newswire)
10:01AM	Alkermes (ALKS) Earnings Expected to Grow: What to Know Ahead of Q1 Release (Zacks)
Apr-11-24 02:18PM	The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks (Investor's Business Daily)
10:15AM	Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study (Zacks)
10:00AM	Alkermes' Innovations Are Transforming Mental Health Treatments (GuruFocus.com)
09:45AM	Loading…
Apr-10-24 09:45AM	Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term (Zacks)
Apr-09-24 12:38PM	BlackBerry, Alkermes rise; Neogen, Tilray Brands fall, Tuesday, 4/9/2024 (Associated Press Finance)
07:00AM	Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia (PR Newswire)
Apr-08-24 07:00AM	Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society (PR Newswire)
Apr-02-24 12:10PM	Why Alkermes (ALKS) is Poised to Beat Earnings Estimates Again (Zacks)
Mar-18-24 07:01PM	Insider Sell: SVP, Chief Commercial Officer Christian Nichols Sells Shares of Alkermes PLC (ALKS) (GuruFocus.com)
Mar-15-24 06:15PM	Alkermes (ALKS) Stock Moves -0.45%: What You Should Know (Zacks)
Mar-13-24 12:45PM	3 Reasons Why Alkermes (ALKS) Is a Great Growth Stock (Zacks)
Mar-12-24 09:50AM	Here's Why Alkermes (ALKS) is a Strong Momentum Stock (Zacks)
Mar-10-24 10:00AM	10 Alternatives to Antidepressant Medications (Insider Monkey)
09:45AM	Loading…
Mar-08-24 09:45AM	Here's Why Alkermes (ALKS) is a Strong Growth Stock (Zacks)
Mar-07-24 06:15PM	Why Alkermes (ALKS) Outpaced the Stock Market Today (Zacks)
07:00AM	Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors (PR Newswire)
Feb-29-24 06:15PM	Alkermes (ALKS) Stock Declines While Market Improves: Some Information for Investors (Zacks)
Feb-23-24 09:50AM	Why Alkermes (ALKS) is a Top Momentum Stock for the Long-Term (Zacks)
Feb-21-24 09:45AM	Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term (Zacks)
Feb-16-24 10:18AM	Alkermes plc (NASDAQ:ALKS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-15-24 02:40PM	Alkermes Stock Gets RS Rating Upgrade; Profits Surge (Investor's Business Daily) +16.33%
01:34PM	Alkermes' (ALKS) Q4 Earnings & Revenues Surpass Estimates (Zacks)
09:30AM	Compared to Estimates, Alkermes (ALKS) Q4 Earnings: A Look at Key Metrics (Zacks)
07:37AM	Alkermes PLC (ALKS) Reports Strong 2023 Financial Results and Sets Positive Outlook for 2024 (GuruFocus.com)
07:30AM	Alkermes: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024 (PR Newswire)
Feb-12-24 09:16AM	Exploring Analyst Estimates for Alkermes (ALKS) Q4 Earnings, Beyond Revenue and EPS (Zacks)
Feb-08-24 04:10PM	7 Biotech Stocks Fighting Americas Deadliest Diseases (InvestorPlace)
04:00PM	Loading…
04:00PM	Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024 (PR Newswire)
10:00AM	Alkermes (ALKS) to Report Q4 Results: Wall Street Expects Earnings Growth (Zacks)
Feb-07-24 06:15PM	Alkermes (ALKS) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks)
Feb-02-24 02:15AM	The 3 Best Biotech Stocks to Invest in for Big Gains in 2024 (InvestorPlace)
Feb-01-24 06:15PM	Alkermes (ALKS) Stock Dips While Market Gains: Key Facts (Zacks)
05:00PM	3 Top Pharma Stocks to Buy Now: February 2024 (InvestorPlace)
Jan-30-24 12:10PM	Why Alkermes (ALKS) Could Beat Earnings Estimates Again (Zacks)
Jan-26-24 06:15PM	Alkermes (ALKS) Registers a Bigger Fall Than the Market: Important Facts to Note (Zacks)
Jan-15-24 04:51PM	The 3 Most Undervalued Biotech Stocks to Buy in January (InvestorPlace)
Jan-12-24 06:15PM	Alkermes (ALKS) Outpaces Stock Market Gains: What You Should Know (Zacks)
Jan-03-24 04:00PM	Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
07:00AM	Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI (olanzapine and samidorphan) (PR Newswire)
Dec-27-23 11:45AM	Equal Opportunity and Respect: Diversity, Inclusion and Belonging at Alkermes (ACCESSWIRE)
Dec-22-23 06:15PM	Alkermes (ALKS) Outperforms Broader Market: What You Need to Know (Zacks)
Dec-20-23 02:15PM	11 Most Promising Psychedelic Stocks According to Hedge Funds (Insider Monkey)
12:15PM	Corporate Governance at Alkermes (ACCESSWIRE)
Dec-18-23 01:45PM	Alkermes' Commitment to Integrity and Compliance (ACCESSWIRE)
Dec-14-23 10:45AM	Alkermes' Culture of Employee Engagement and Wellness (ACCESSWIRE)
06:05AM	Alkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk (PR Newswire)
Dec-13-23 04:08AM	12 Best Growth Stocks to Buy According to Billionaire Ray Dalios Bridgewater Associates (Insider Monkey)
Dec-11-23 02:30PM	Patient Advocacy and Community Engagement at Alkermes (ACCESSWIRE)
Dec-01-23 06:16PM	Uber Technologies, Jabil and Builders FirstSource Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 (PR Newswire)
Nov-29-23 03:15PM	Pharmaceuticals in the Environment (ACCESSWIRE)
Nov-24-23 11:31AM	Why Is Alkermes (ALKS) Down 1.3% Since Last Earnings Report? (Zacks)
Nov-21-23 04:00PM	Alkermes to Participate in Two Upcoming Investor Conferences (PR Newswire)
11:45AM	Environmental Protection & Sustainability at Alkermes (ACCESSWIRE)
Nov-20-23 01:45PM	Alkermes Celebrates #Movember for Mens Health Awareness Month (ACCESSWIRE)
Nov-16-23 10:30AM	Alkermes' Waste Optimization Highlights (ACCESSWIRE) +6.03%
Nov-15-23 08:57AM	Mural Oncology wants to paint a new picture in IL-2 after Alkermes spinout (FierceBiotech.com)
07:15AM	Alkermes separates cancer drug business as new company Mural (BioPharma Dive)
07:00AM	Alkermes Completes Separation of Oncology Business (PR Newswire)
Nov-14-23 01:45PM	Our Commitment to Caregivers (ACCESSWIRE)
10:33AM	Alkermes (ALKS) Proprietary Drugs Aid Growth Amid Competition (Zacks)
05:50AM	3 Growth Stocks Set to Dominate the Decade (InvestorPlace)
Nov-13-23 09:50PM	Jim Simons Stock Portfolio: 12 Biggest Healthcare Stocks (Insider Monkey)
12:45PM	Product Stewardship and Environmental Impact at Alkermes (ACCESSWIRE)
Nov-10-23 03:00PM	Caring for Caregivers: Alkermes Celebrates National Caregivers Month (ACCESSWIRE)
Nov-09-23 11:12AM	7 Healthcare Stocks That Are Poised to Become the Next Unicorns (InvestorPlace)
Nov-08-23 11:30AM	Environmental Health and Safety at Alkermes (ACCESSWIRE)
Nov-07-23 04:00PM	Alkermes to Participate in the Jefferies London Healthcare Conference (PR Newswire)
Nov-04-23 12:16PM	12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds (Insider Monkey)
Oct-31-23 05:08PM	Alkermes Announces Effectiveness of Mural Oncology Form 10 Registration Statement (PR Newswire)
01:30PM	Operating and Growing Responsibly at Alkermes (ACCESSWIRE)
Oct-26-23 12:00PM	Alkermes (ALKS) Down Despite Q3 Earnings & Revenue Beat (Zacks) +5.33%
10:37AM	Alkermes plc (NASDAQ:ALKS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Oct-25-23 12:38PM	Why Alkermes Stock Is Sinking Today (Motley Fool) -7.39%
09:30AM	Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
07:23AM	Alkermes: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Alkermes plc Reports Third Quarter 2023 Financial Results (PR Newswire)
Oct-24-23 09:51AM	Foot Locker downgraded, Amazon initiated: Wall Street's top analyst calls (The Fly)
Oct-23-23 04:00PM	Alkermes Plummets In Huge Volume. Why One Analyst Says The Reaction Is Overdone. (Investor's Business Daily) -9.59%
02:00PM	Alkermes CEO Reflects on Living Company Purpose (ACCESSWIRE)
08:00AM	Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress (PR Newswire)
Oct-19-23 10:01AM	Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-18-23 06:15PM	Alkermes (ALKS) Dips More Than Broader Market: What You Should Know (Zacks)
04:00PM	Alkermes to Report Third Quarter Financial Results on October 25, 2023 (PR Newswire)
Oct-16-23 12:30PM	Celebrating Global Diversity Awareness Month at Alkermes (ACCESSWIRE)
Oct-13-23 10:45AM	Take Time During Mental Health Awareness Week To Review These Resources (ACCESSWIRE)
Oct-11-23 12:00PM	Alkermes Proudly Announces Release of 2023 Corporate Responsibility Report (ACCESSWIRE)
Oct-10-23 05:00PM	Mural Oncology to Host Investor Webcast on October 17 (PR Newswire)
07:00AM	Alkermes to Present First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress (PR Newswire)
Sep-21-23 01:00PM	Alkermes Pauses To Recognize National Ovarian Cancer Awareness Month (ACCESSWIRE)
Sep-19-23 11:05AM	Alkermes Pathways Research Awards Is Now Accepting Applications! (ACCESSWIRE)
Sep-18-23 01:15PM	Alkermes Commemorates World Suicide Prevention Day (ACCESSWIRE)
Sep-15-23 06:15PM	Alkermes (ALKS) Stock Moves -0.84%: What You Should Know (Zacks)
Sep-13-23 10:50AM	For Potential Alkermes Buyers, There's a Key Price Level to Watch (TheStreet.com)
Sep-11-23 07:00AM	Alkermes Presents Clinical and Real-World Data at 36th Annual Psych Congress (PR Newswire)
Sep-08-23 06:15PM	Alkermes (ALKS) Stock Sinks As Market Gains: What You Should Know (Zacks)
Sep-07-23 03:15PM	Alkermes Announces Launch of 6th Annual Alkermes Pathways Research Awards(R) Program (ACCESSWIRE)
11:31AM	Novavax (NVAX) Up 36.8% Since Last Earnings Report: Can It Continue? (Zacks)

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nichols Christian Todd	SVP, Chief Commercial Officer	Mar 18 '24	Sale	28.10	10,417	292,740	65,911	Mar 18 04:02 PM
Parisi Samuel Joseph	VP, Finance (Interim PAO)	Feb 27 '24	Sale	29.65	2,559	75,874	7,717	Feb 27 04:09 PM
LAURENCIN CATO T	Director	Feb 15 '24	Option Exercise	22.52	2,690	60,579	17,859	Feb 16 04:01 PM
LAURENCIN CATO T	Director	Feb 15 '24	Sale	31.85	2,690	85,676	15,169	Feb 16 04:01 PM
LAURENCIN CATO T	Director	Jun 08 '23	Option Exercise	22.97	2,638	60,595	10,117	Jun 08 04:31 PM
LAURENCIN CATO T	Director	Jun 08 '23	Sale	31.85	2,638	84,020	7,479	Jun 08 04:31 PM
LAURENCIN CATO T	Director	Jun 07 '23	Option Exercise	22.97	2,800	64,316	10,279	Jun 07 05:12 PM
LAURENCIN CATO T	Director	Jun 07 '23	Sale	31.50	2,800	88,200	7,479	Jun 07 05:12 PM
Nichols Christian Todd	SVP, Chief Commercial Officer	May 30 '23	Option Exercise	20.43	19,634	401,123	68,118	May 30 08:16 PM
Nichols Christian Todd	SVP, Chief Commercial Officer	May 30 '23	Sale	28.93	27,134	784,862	40,984	May 30 08:16 PM
Wysenski Nancy	Director	May 09 '23	Option Exercise	31.13	41,250	1,284,112	57,079	May 10 04:34 PM
Wysenski Nancy	Director	May 09 '23	Sale	31.24	41,250	1,288,786	15,829	May 10 04:34 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALKS

Alkermes plc

Upgrade your FINVIZ experience